197 related articles for article (PubMed ID: 29090520)
1. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.
Kahn JM; Cole PD; Blonquist TM; Stevenson K; Jin Z; Barrera S; Davila R; Roberts E; Neuberg DS; Athale UH; Clavell LA; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Sallan SE; Silverman LB; Kelly KM
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090520
[TBL] [Abstract][Full Text] [Related]
2. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.
Vrooman LM; Stevenson KE; Supko JG; O'Brien J; Dahlberg SE; Asselin BL; Athale UH; Clavell LA; Kelly KM; Kutok JL; Laverdière C; Lipshultz SE; Michon B; Schorin M; Relling MV; Cohen HJ; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2013 Mar; 31(9):1202-10. PubMed ID: 23358966
[TBL] [Abstract][Full Text] [Related]
3. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB
J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603
[TBL] [Abstract][Full Text] [Related]
4. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
5. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.
Finkelstein Y; Blonquist TM; Vijayanathan V; Stevenson KE; Neuberg DS; Silverman LB; Vrooman LM; Sallan SE; Cole PD
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27957785
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000).
Silverman LB; Stevenson KE; O'Brien JE; Asselin BL; Barr RD; Clavell L; Cole PD; Kelly KM; Laverdiere C; Michon B; Schorin MA; Schwartz CL; O'Holleran EW; Neuberg DS; Cohen HJ; Sallan SE
Leukemia; 2010 Feb; 24(2):320-34. PubMed ID: 20016537
[TBL] [Abstract][Full Text] [Related]
7. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
Silverman LB; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Arkin S; Declerck L; Cohen HJ; Sallan SE
Blood; 2001 Mar; 97(5):1211-8. PubMed ID: 11222362
[TBL] [Abstract][Full Text] [Related]
9. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).
Bona K; Blonquist TM; Neuberg DS; Silverman LB; Wolfe J
Pediatr Blood Cancer; 2016 Jun; 63(6):1012-8. PubMed ID: 26913850
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of Dana Farber Consortium Protocol in newly diagnosed Egyptian adolescents and young adults with acute lymphoblastic leukemia: Tanta experience.
Elashtokhy HEA; Elgohary HE; Eldeep BB; Gaber SM; Elbedewy TA
J Egypt Natl Canc Inst; 2021 Apr; 33(1):9. PubMed ID: 33826046
[TBL] [Abstract][Full Text] [Related]
11. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
12. Bony morbidity in children treated for acute lymphoblastic leukemia.
Strauss AJ; Su JT; Dalton VM; Gelber RD; Sallan SE; Silverman LB
J Clin Oncol; 2001 Jun; 19(12):3066-72. PubMed ID: 11408503
[TBL] [Abstract][Full Text] [Related]
13. Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials.
Valtis YK; Stevenson KE; Place AE; Silverman LB; Vrooman LM; Gotti G; Brunner AM; Nauffal M; DeAngelo DJ; Luskin MR
Blood Adv; 2022 Jan; 6(1):72-81. PubMed ID: 34610104
[TBL] [Abstract][Full Text] [Related]
14. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
15. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
16. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.
LeClerc JM; Billett AL; Gelber RD; Dalton V; Tarbell N; Lipton JM; Barr R; Clavell LA; Asselin B; Hurwitz C; Schorin M; Lipshultz SE; Declerck L; Silverman LB; Cohen HJ; Sallan SE
J Clin Oncol; 2002 Jan; 20(1):237-46. PubMed ID: 11773175
[TBL] [Abstract][Full Text] [Related]
17. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research Database.
Högler W; Wehl G; van Staa T; Meister B; Klein-Franke A; Kropshofer G
Pediatr Blood Cancer; 2007 Jan; 48(1):21-7. PubMed ID: 16317756
[TBL] [Abstract][Full Text] [Related]
18. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.
Moghrabi A; Levy DE; Asselin B; Barr R; Clavell L; Hurwitz C; Samson Y; Schorin M; Dalton VK; Lipshultz SE; Neuberg DS; Gelber RD; Cohen HJ; Sallan SE; Silverman LB
Blood; 2007 Feb; 109(3):896-904. PubMed ID: 17003366
[TBL] [Abstract][Full Text] [Related]
19. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995).
Silverman LB; Declerck L; Gelber RD; Dalton VK; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin MA; Lipton JM; Cohen HJ; Sallan SE
Leukemia; 2000 Dec; 14(12):2247-56. PubMed ID: 11187916
[TBL] [Abstract][Full Text] [Related]
20. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
